Drug intelligence / Profile preview

99mTc-Res-AuNP

Development stage: Unknown
Lead developer: Panjab University
Modality: Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

"99mTc-Res-AuNP" is a radiolabeled nanoparticle formulation composed of gold nanoparticles (AuNPs) loaded with resveratrol and labeled with Technetium-99m (\(^{99m}\)Tc). It is designed for targeted delivery and physiological uptake in cancer tissues, particularly colon cancer, enhancing the diagnostic and therapeutic potential of gold nanoparticles. The compound leverages the radiosensitizing properties of gold and the potential biological activity of resveratrol.

Beyond the preview

Go deeper on 99mTc-Res-AuNP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-Res-AuNP.

Explore the full profile